Biochemical abnormalities in coronavirus disease 2019 (COVID-19): a comparison of White vs. ethnic minority populations in the U.K.

David R. Taylor[1], Devon Buchanan[1], Wiaam Al-Hasani[1], Jessica Kearney[2], Tina Mazaheri[1], Ruvini N.K Ranasinghe[1], Georgios K. Dimitriadis[2] and Royce P. Vincent[1]

Departments of [1]Clinical Biochemistry (Viapath) and [2]Endocrinology, King's College Hospital NHS Foundation Trust, London, SE5 9RS

Short Title: Biochemistry at presentation in ethnic minority and White COVID-19 patients at hospital presentation

Address for correspondence:

David Taylor

Department of Clinical Biochemistry (Viapath),

First Floor, Bessemer Wing,

King's College Hospital

Denmark Hill

London SE5 9RS

Tel: 0203 299 3009

Email: davidtaylor8@nhs.net

Acknowledgements: None

Declaration of conflicting interests: The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Funding: The author(s) received no financial support for the research, authorship and/or publication of this article

Ethical approval: Approved by the King's College Hospital Clinical Audit Committee. Ref ENDOC01

Guarantor: DRT

Contributorship: All authors contributed to design and execution of the study. All authors reviewed and edited the article and approved the final version of the manuscript.

ORCID iD

David R Taylor https://orcid.org/0000-0003-1385-3961

Devon Buchanan https://orcid.org/0000-0003-1175-7212

Tina Mazaheri https://orcid.org/0000-0001-8655-2372

Jessica Kearney https://orcid.org/0000-0001-7216-4408

Ruvini N K Ranasinghe https://orcid.org/0000-0002-6603-8322

Georgios K Dimitriadis https://orcid.org/0000-0002-6662-804X

Royce P Vincent https://orcid.org/0000-0003-0743-4189

Abstract

Aims: Public Health England have identified that in coronavirus disease 2019 (COVID-19), death rates amongst ethnic minorities far exceeds that of the White population. Whilst the increase in ethnic minorities is likely to be multi-factorial; to date, no studies have looked to see whether values for routine clinical biochemistry parameters differ between ethnic minority and White individuals.

Methods: Baseline biochemical data for 22 common tests from 311 SARs-CoV-2 positive patients presenting to hospital in April 2020 in whom ethnicity data was available was retrospectively collected and evaluated. Data comparisons between ethnic minority and White groups were made for all patient data and for the subset of patients subsequently admitted to intensive care.

Results: When all patient data were considered, the ethnic minority population had statistically significant higher concentrations of CRP, AST and GGT, whilst troponin T was higher in the White group. A greater proportion of ethnic minority patients were subsequently admitted to intensive care, but when the presenting biochemistry of this subset of patients was compared, no significant differences were observed between ethnic minority and White groups.

Conclusion: Our data show for the first time that routine biochemistry at hospital presentation in COVID-19 differs between ethnic minority and White groups. Amongst the markers identified, CRP was significantly higher in the ethnic minority group pointing towards an increased tendency for severe inflammation in this group.

Keywords: SARs-CoV-2, COVID-19, ethnic minority, ethnicity, routine biochemistry

Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CK, creatine kinase; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; CRP, C-reactive protein;

CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; GGT, gamma-glutamyltransferase; IL-6, interleukin-6; ITU, intensive care unit; LDH, lactate dehydrogenase; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Introduction

In December 2019 a new highly infectious disease, coronavirus disease 2019 (COVID-19), was first reported in Wuhan, Hubei Province, China.[1,2] The causative agent of COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has since spread worldwide resulting in 88 387 352 cases and 1 919 204 deaths as of January 10 2021, according to a weekly epidemiological update from the World Health Organization.[3]

Severe or fatal COVID-19 infection has been associated with gross changes in Clinical Biochemistry parameters. To date, common findings include increases of markers of tissue damage (creatine kinase (CK), lactate dehydrogenase (LDH), myoglobin, troponin), inflammation (C-reactive protein (CRP), ferritin, procalcitonin), renal impairment (increased creatinine and urea) and liver dysfunction (increases of amino transferases and bilirubin, decreased albumin).[4,5] Severe COVID-19 infection has also been associated with low serum sodium, potassium and calcium.[6] Biochemical data can be predictive in COVID-19; parameters which are predictive of death include increased CRP, LDH, aspartate aminotransferase (AST), troponin I and creatinine and low albumin.[7-10]

In a review by Public Health England, death rates amongst Black, Asian and other minority ethnicities COVID-19 positive people were shown to be significantly higher than in White British people.[11] Death rates in those of Bangladeshi background were twice as high, and for other ethnic minority groups between 10-50% higher, after taking into account age, sex, deprivation, and region. The cause of these discrepancies is unclear, but likely to be multifactorial. We have previously assessed differences in cardiac markers at hospital presentation in ethnic minority and White groups in COVID-19[12], but to date, no study has investigated whether more routine biochemistry broadly differ in this setting, nor whether any differences provide prognostic value. To address these questions, we retrospectively reviewed admission biochemistry for a cohort of COVID-19 positive patients in whom ethnicity data

was available. We compared all data between ethnic minority and White groups and in a subset of patients who were subsequently admitted to an intensive care unit (ITU).

Methods

This retrospective observational study was conducted at King's College Hospital NHS Foundation Trust, a busy teaching hospital located in South London. Patients with baseline biochemistry data were included in the analysis if they were admitted between the 1st and 28th of April 2020 (the period of peak admission rates in London during the first wave of the pandemic), had positive (RT-PCR) SARS-CoV-2 serology and if ethnicity data was available. The first available result after hospital admission for the following 22 biochemical tests were obtained for each patient: albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, adjusted calcium, CK, creatinine, CRP, estimated glomerular filtration rate (eGFR), ferritin, gamma-glutamyl transferase (GGT), LDH, magnesium, sodium, N-terminal prohormone of brain natriuretic peptide (NT-proBNP), procalcitonin, phosphate, potassium, troponin T, total protein and urea. Inclusion of admission biochemical data in the ITU analyses was made if the individual was subsequently transferred to ITU within 28 days of admission. Electronic patient records were accessed for body mass index (BMI) data and to assess for the presence of pre-existing common comorbidities in each patient at baseline (defined as histories of diabetes mellitus, cardiovascular disease (CVD), chronic kidney disease (CKD), hypertension and chronic obstructive pulmonary disease ((COPD) or asthma). Patients were classified as "White" or "ethnic minority" using the Office for National Statistics list of ethnic groups. All biochemical data were generated using Roche c-702 and e-801 analytical platforms (Roche, Burgess Hill, U.K.), using blood samples collected into serum separator tubes (Greiner Bio-One Ltd, Stonehouse, U.K.). All tests are accredited by the United Kingdom Accreditation Service to iso15189. The methods used for ALT and AST included pyridoxal phosphate, with the LDH assay being measured in the L-lactate to pyruvate direction. Test requests on samples for which haemolysis, icteric

or lipaemic indices exceeded the manufacturer's limits for that particular test were cancelled and not included in analyses. Biochemical test data were tested for normality using the Kolmogorov-Smirnov test, and with the exception of albumin, adjusted calcium, globulin, LDH, magnesium, potassium and total protein, were found to be not normally distributed so group comparisons of biochemical data were made using a two tailed Mann-Whitney U test. Data are reported as median (interquartile range). Values of $P < 0.05$ were taken as statistically significant. The proportion of abnormal results for each test studies was compared using a Chi-square test. Data comparisons were made using R version 3.6.2 (R Foundation for Statistical Computing, Vienna, Austria).[13]

Results

Ethnic minority patients presenting in April 2020 with COVID-19, in comparison to those from White ethnic groups, were younger (median age 65 vs. 75 years) and predominantly male (64% vs. 52%, Table 1). Ethnic minority individuals were more likely to subsequently require ITU admission (19% patients vs. 13% White patients, Table 1). A history of diabetes mellitus was more common in the ethnic minority group, whilst CVD history was more common in the White group. Frequencies of hypertension, CKD and respiratory disorders (COPD or asthma) were similar in ethnic minority and White groups (Table 1). BMI data was incomplete across the two groups. Of available data (151/211 ethnic minority patients and 70/100 White patients), BMI was similar in the two groups. Median BMI (interquartile range) in the ethnic minority group was 28.8 kg/m^2 (24.7 – 33.5) and in the White group 28.7 kg/m^2 (23.3 – 32.0).

Review of baseline biochemistry data for all patients revealed statistically significant differences between the two groups for a number of common analytes (Table 2). Of these results, 86% were obtained on hospital admission day, with 97% of test results being acquired within the first 3 days of the patients hospital stay. The majority of patients in the study had abnormal CRP results, however, CRP concentrations were higher in the ethnic minority group (median value 111.2 mg/L, interquartile

range 66.5 – 181.1) than in the White group (48.1 mg/L, 22.1 – 112.9). Increase of this inflammatory marker was not reflected by ethnicity-related differences in procalcitonin, nor ferritin concentration; almost all patients had elevated ferritin. The median cardiac troponin T was higher, and a greater proportion of patients had abnormal results, in the White group than in the ethnic minority group. Median NT-proBNP concentration was also higher in the White group, although this association did not reach statistical significance. Of markers of liver function, AST and GGT were higher in the ethnic minority group, but ALP lower. A greater proportion of the ethnic minority population also had AST concentrations falling outside the reference interval. ALT, albumin and total bilirubin were not different between the two groups. No differences between ethnic minority and White groups were noted for sodium, potassium, adjusted calcium or phosphate, nor for markers of renal function (creatinine, eGFR and urea). The tissue damage markers, LDH and CK, also showed no ethnicity-specific differences at presentation, with the majority of patients having abnormal values.

When baseline biochemistry data for ethnic minority and White patients that were subsequently admitted to ITU were compared, no statistically significant differences between these groups were observed for any of the analytes studied (Table 3).

Discussion

For the first time, we have shown that there are significant differences at hospital presentation between ethnic minority and White populations in results for a number of routine biochemistry tests. The results of this study are therefore important because they may contribute towards greater understanding of why ethnic minority individuals are at increased risk of death due to COVID-19. The most striking finding from our study is the increase at presentation of CRP in ethnic minority individuals versus White individuals. CRP measurement is now well established as a marker of disease severity in COVID-19.[14] Zhang *et al.*[15] showed that in 140 hospitalized patients with confirmed SARS-CoV-2 infection, in non-severe disease CRP concentrations ranged from 9.5–52.1 mg/L, whilst in

severe disease values ranged from 20.6–87.1 mg/L. In another study, 56.4% of patients with non-severe COVID-19 had CRP above the reference interval, which rose to 81.5% in those with severe disease.[16] Around 20% of patients infected with SARS-CoV-2 progress to having associated life-threatening complications involving acute inflammation associated with a cytokine storm, coagulopathy, septic shock and multiple organ failure.[17] Increased concentrations of interleukin-6 (IL-6) are associated with severe COVID-19 and positively correlate with adverse outcomes.[18,19] The increased concentrations of IL-6 directly result in the liver increasing synthesis of CRP.[18] The results from this study raise the interesting possibility that the higher concentrations of CRP in ethnic minority patients at hospital presentation may mark an increased susceptibility to severe inflammation during their COVID-19 disease course. These differences appear not to be accounted for by a genetic predisposition of ethnic minority individuals to higher CRP levels; median value of CRP in Blacks was 3.0 mg/L vs. 2.3 mg/L in Whites in one study of healthy individuals.[20] The absence of differences between the ethnic minority and White groups for the two other markers of inflammation studied (procalcitonin and ferritin) supports the hypothesis of a specific increased susceptibility to cytokine-mediated adverse incidents in the ethnic minority population.[21] Pre-existing comorbidities including CVD, COPD, diabetes and hypertension are established risk factors for severe disease in the pandemic[22]. Many of these comorbidities are known to promote a pro-inflammatory state, but of these, only diabetes mellitus prevalence was higher in the ethnic minority group than in the White group in our study. It is hypothesised that existing diabetes mellitus may accentuate the inflammation associated with viral infection[23], therefore the increased prevalence of diabetes in the ethnic minority group in our study may be a contributory factor to the increased CRP concentrations at presentation in this group. Like CRP, diabetes has also been shown to be significantly associated with in-hospital mortality[24].

Liver injury in COVID-19 is also associated with disease severity[25]. It is characterised by increased transminases, with increase of AST dominating over ALT[5]. In our study, AST tended to be higher in the ethnic minority population than in the White population whilst ALT did not show any difference between the two groups. However, the increases of transminases seen in both groups were generally mild and unlikely to represent significant liver injury. Although GGT tended to be higher in the ethnic minority population, this difference is likely related to known ethnic differences in this marker.[26] We have previously reported higher, troponin T and NT-ProBNP in the White population than in ethnic minorities[12], although the latter association did not reach statistical significance. Likely contributory factors to these findings are that the White population were older with a higher prevalence of CVD. Elevated troponin has been associated with worse outcomes in COVID-19[27].

In our cohort, although non-White ethnicity and male gender were predictive of ITU admission, no statistically significant differences in biochemistry at presentation were noted for those who were subsequently admitted to ITU compared to the White population, including for CRP. This may suggest that there is no difference in the pathological mechanisms underlying severe COVID-19 which are reflected by routine biochemistry, but that ethnic minority subjects are at an increased risk of developing them.[19] Of course, the association between ethnic minority and severe COVID-19 disease is likely to be complex and incorporate multiple demographic and socioeconomic factors not already captured in this study. In one study, Raisi-Estabragh *et al*.[28] suggested that both the sex and ethnic patterns of COVID-19 are not adequately explained by variation in cardio-metabolic factors, 25(OH)-vitamin D concentrations or socio-economic factors; clearly there is a need for more research required to define the mechanism of increased ethnic minority risk.

This study has some limitations. Although the facts that 86% of total test results were obtained on admission day and 97% within three days of admission would argue against the possibility of

differences in care between ethnic groups whilst in hospital, we cannot exclude the possibility that biochemical differences are not contributed to by variance in the disease stage at which different ethnic groups accessed hospital care. In the patients who were admitted to ITU during their hospital stay, the number of results for some tests may be too low to identify true differences between the two groups. The outcomes of ITU patients (requirement for mechanical ventilation/continuous positive airway pressure support and morbidity/mortality) were also not available to allow interrogation of the biochemistry with respect to endpoint. In addition, the majority of the ethnic minority group were of Black ethnicity, (149/211 of all ethnic minority cases, all ethnic minority individuals in ITU), so caution is advised in making generalisations across all non-White ethnic groups. Finally, for some tests in the study, such as procalcitonin, only a small number of tests were performed overall.

In conclusion, the major finding of this study is that ethnic minority patients have higher CRP concentrations at presentation, indicating a more severe acute inflammation. This may augment existing co-morbidities characterised by chronic inflammation which may be more prevalent in the ethnic minority population such as diabetes, pointing towards an increased tendency for severe inflammation in this group.

Key messages:

- In the U.K, it has been shown that ethnic minorities have poorer outcomes in COVID-19 relative to those of the White population, including an increased risk of death
- In this study, we show that there are significant differences between ethnic minority and White populations in routine clinical biochemistry parameters at presentation to hospital with COVID-19
- Amongst the markers identified, C-reactive protein was significantly higher in the ethnic minority group, pointing towards an increased tendency for severe inflammation in this group, which may contribute towards the poorer outcomes in this group reported previously

References

1. Zhu N, Zhang D, Wang W, et al; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med* 2020; 382: 727-733.
2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; 395: 497-506.
3. World Health Organization. Weekly epidemiological update - 12 January 2021. Accessed January 17, 2021. https://www.who.int/publications/m/item/weekly-epidemiological-update---12-january-2021
4. Henry BM, de Oliveira MHS, Benoit S, et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. *Clin Chem Lab Med* 2020; 58: 1021-1028.
5. Bloom PP, Meyerowitz EA, Reinus Z, et al. Liver Biochemistries in Hospitalized Patients With COVID-19. Hepatology 2020; May 16. doi: 10.1002/hep.31326. Online ahead of print.
6. Lippi G, South AM and Henry BM. Electrolyte imbalances in patients with severe coronavirus disease 2019 (COVID-19). *Ann Clin Biochem* 2020; 57: 262–265.
7. Bonetti G, Manelli F, Patroni A, et al. Laboratory predictors of death from coronavirus disease 2019 (COVID-19) in the area of Valcamonica, Italy. *Clin Chem Lab Med* 2020; 58: 1100-1105.
8. Galloway JB, Norton S, Barker RD, et al. A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: An observational cohort study. *J Infect* 2020; 81: 282-288.
9. Lei F, Ye-Mao Liu Y-M, Feng Zhou F et al. Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China. *Hepatology* 2020; doi: 10.1002/hep.31301. Online ahead of print.

10. Du RH, Liang LR, Yang CQ, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. *Eur Respir J* 2020; 55: 2000524.
11. Public Health England. Disparities in the risk and outcomes of COVID-19. PHE, 2020.
12. Ranasinghe RNK, Taylor DR, Mazaheri T, et al. Cardiac markers in Black, Asian and minority ethnic (BAME) patients with COVID-19. *J Clin Pathol* 2020; Dec 10 jclinpath-2020-207188. doi: 10.1136/jclinpath-2020-207188. Online ahead of print.
13. R Core Team. *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for Statistical Computing 2019.
14. Potempa LA , Rajab IM, Hart PC, et al. Insights Into the Use of C-Reactive Protein as a Diagnostic Index of Disease Severity in COVID-19 Infections. *Am J Trop Med Hyg* 2020; doi: 10.4269/ajtmh.20-0473. Online ahead of print.
15. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy* 2020; 75: 1730-1741.
16. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020; 382: 1708–1720.
17. He F, Deng Y and Li W. Coronavirus Disease 2019: What We Know? *J Med Virol* 2020; 92: 719-725.
18. Moore JB and June CH. Cytokine Release Syndrome in Severe COVID-19. *Science* 2020; 368: 473-474.
19. Aziz M, Fatima R and Assaly R. Elevated interleukin-6 and Severe COVID-19: A Meta-Analysis. *J Med Virol* 2020; 10.1002/jmv.25948. doi: 10.1002/jmv.25948. Online ahead of print.
20. Khera A, McGuire DK, Murphy SA, et al. Race and Gender Differences in C-reactive Protein Levels. *J Am Coll Cardiol* 2005;46(3):464-9. doi: 10.1016/j.jacc.2005.04.051.
21. Vepa A, Bae JP, Ahmed F, et al. COVID-19 and ethnicity: A novel pathophysiological role for inflammation. *Diabetes Metab Syndr* 2020; 14: 1043–1051.

22. Del Sole F, Farcomeni A, Loffredo L, et al. Features of severe COVID-19: A systematic review and meta-analysis. *Eur J Clin Invest* 2020; 50: e13378.

23. Lim S, Bae JH, Kwon H-S, et al. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. *Nat Rev Endocrinol* 2021; 17: 11-30.

24. Silverio A, Di Maio M, Citro R, et al. Cardiovascular risk factors and mortality in hospitalized patients with COVID-19: systematic review and meta-analysis of 45 studies and 18,300 patients. *BMC Cardiovasc Disord* 2021; 21(1):23.

25. Anirvan P, Bharali P, Gogoi M, et al. Liver injury in COVID-19: The hepatic aspect of the respiratory syndrome - what we know so far. *World J Hepatol* 2020; 12(12):1182-1197.

26. Stranges S, Freudenheim JL, Muti P, et al. Greater hepatic vulnerability after alcohol intake in African Americans compared with Caucasians: a population-based study. *J Natl Med Assoc* 2004; 96: 1185-92.

27. Tersalvi G, Vicenzi M, Calabretta D, et al. Elevated troponin in patients with Coronavirus Disease 2019 (COVID-19): possible mechanisms. *J Card Fail* 2020; 26: 470-5.

28. Raisi-Estabragh Z, McCracken C, Bethell MS, et al. Greater risk of severe COVID-19 in Black, Asian and Minority Ethnic populations is not explained by cardiometabolic, socioeconomic or behavioural factors, or by 25(OH)-vitamin D status: study of 1326 cases from the UK Biobank. *J Public Health (Oxf)* 2020; fdaa095. doi: 10.1093/pubmed/fdaa095. Online ahead of print. PMID: 32556213

Tables

Table 1. Demographic data in BAME and White groups. Age data presented as median (interquartile range).

	Ethnic minority	White
All patient data		
Number	211	100
Age (years)	65 (55-78)	75 (66-84)
Male/female (%)	64/36	52/48
Pre-existing comorbidities:		
Diabetes (%)	54	31
CVD (%)	25	50
CKD (%)	31	28
Hypertension (%)	49	49
COPD/Asthma (%)	30	27
Patients subsequently admitted to intensive care		
Number (% total)	39 (18)	13 (13)
Age (years)	59 (52-65)	65 (57-71)
Male/female (%)	77/23	77/23

Table 2. Biochemistry at presentation (all patient data). P values <0.05 were taken as statistically significant. N/A = Chi-squared test was not applicable to data where only abnormal results were recorded.

Test	Number of results		Test result (Median (interquartile range))			Abnormal results (%)		
	Ethnic minority	White	Ethnic minority	White	P-value	Ethnic minority	White	P-value
Albumin (g/L)	211	100	37.0 *(34.0 – 39.5)*	37.5 *(34.0 – 41.0)*	0.247	30	33	0.668
ALP (IU/L)	209	100	74.0 *(57.0 – 98.0)*	84.0 *(63.0 – 102.5)*	0.039	12	17	0.302
ALT (IU/L)	104	33	41.0 *(27.8 – 58.0)*	32.0 *(17.0 – 70.0)*	0.078	29	27	1.000
AST (IU/L)	206	99	52.0 *(35.2 – 76.0)*	40.0 *(28.0 – 71.5)*	0.008	75	56	0.001
Total bilirubin (µmol/L)	211	100	9.0 *(6.5 – 13.0)*	9.0 *(6.0 – 14.0)*	0.617	6	6	1.000
Adjusted calcium (mmol/L)	183	81	2.3 *(2.2 – 2.4)*	2.3 *(2.2 -2.4)*	0.537	19	22	0.604
CK (IU/L)	63	31	270.0 *(111.5 – 1139.0)*	163.0 *(63.5 – 725.0)*	0.447	67	52	0.236
Creatinine (µmol/L)	211	100	106.0 *(80.0 – 159.5)*	100.0 *(76.8 – 138.5)*	0.208	40	35	0.442
CRP (mg/L)	209	98	111.2 *(66.5 – 181.1)*	48.1 *(22.1 – 112.9)*	<0.001	97	93	0.153
eGFR (ml/min/1.73m^2)	210	99	58.0 *(34.0 – 78.8)*	55.0 *(38.5 – 86.0)*	0.447	56	65	0.222
Ferritin (µg/L)	91	35	916.0 (579.0 – 1815.5)	1,046.0 *(386.5 – 1859.0)*	0.208	90	86	0.699
GGT (IU/L)	209	100	57.0 *(32.0 – 99.0)*	41.0 *(23.0 – 83.2)*	0.030	51	40	1.000
LDH (IU/L)	48	12	467.0 *(351.2 – 631.2)*	503.5 *(457.5 – 634.0)*	0.432	92	92	1.000
Magnesium (mmol/L)	183	81	0.9 *(0.8 – 1.0)*	0.8 *(0.8 – 1.0)*	0.028	28	32	0.582
Sodium (mmol/L)	211	100	137.0 *(134.0 – 140.0)*	137.0 *(134.0 – 140.30)*	0.521	35	35	1.000
NT-proBNP (ng/L)	34	13	221.5 *(90.8 – 1077.5)*	427.0 *(141.0 – 1678.0)*	0.274	66	77	0.448
Procalcitonin (µg/L)	28	8	1.2 *(0.4 – 11.4)*	0.7 *(0.3 – 2.5)*	0.594	100	100	N/A
Phosphate (mmol/L)	181	81	1.0 *(0.8 – 1.2)*	1.0 *(0.9 – 1.2)*	0.145	36	30	0.395
Potassium (mmol/L)	208	98	4.2 *(3.8 – 4.7)*	4.3 *(3.9 – 4.8)*	0.215	24	19	0.502
Troponin T (ng/L)	122	45	19.0 *(8.2 – 52.2)*	35.0 *(16.0 – 74.0)*	0.023	62	82	0.024

Total protein (g/L)	210	100	71.0 *(67.0 – 74.0)*	68.5 *(64.0 – 71.2)*	<0.001	12	13	0.929
Urea (mmol/L)	211	99	7.0 *(4.6 – 14.3)*	8.7 *(5.9 – 13.9)*	0.059	64	67	0.738

Table 3. Biochemistry at hospital presentation in patients subsequently admitted to intensive care. P values <0.05 were taken as statistically significant. N/A = Chi-squared test was not applicable to data where only abnormal results were recorded.

Test	Number of results		Test result (Median (interquartile range))			Abnormal results (%)		
	Ethnic minority	White	Ethnic minority	White	P-value	Ethnic minority	White	P-value
Albumin (g/L)	39	13	38.0 (34.0 – 39.0)	35.0 (32.0 – 37.0)	0.167	28	38	0.729
ALP (IU/L)	39	13	81.0 (57.0 – 107.0)	83.0 (74.0 – 132.0)	0.459	21	31	0.704
ALT (IU/L)	36	10	44.5 (30.0 – 68.5)	76.0 (41.0 – 154.5)	0.432	36	50	0.667
AST (IU/L)	39	13	68.0 (48.5 – 136.0)	65.0 (44.0 – 183.0)	0.966	87	77	0.657
Total bilirubin (µmol/L)	39	13	8.0 (7.0 – 13.0)	11.0 (8.0 – 18.0)	0.203	5	23	0.175
Adjusted calcium (mmol/L)	39	13	2.3 (2.2 – 2.4)	2.3 (2.2 – 2.3)	0.958	23	31	0.853
CK (IU/L)	29	10	632.0 (161.0 – 1687.0)	142.5 (83.2 – 1174.2)	0.311	79	40	0.054
Creatinine (µmol/L)	39	13	110.0 (81.0 – 211.0)	130.0 (110.0 – 182.0)	0.310	41	62	0.335
CRP (mg/L)	39	13	157.0 (111.4 – 257.1)	168.4 (40.9 – 251.8)	0.616	100	100	N/A
eGFR (ml/min/1.73m^2)	39	13	59.0 (28.0 – 83.0)	39.0 (32.0 – 58.0)	0.295	51	85	0.073
Ferritin (µg/L)	34	10	1,054.5 (718.0 – 1981.0)	1,822.0 (1018.2 – 2507.5)	0.245	97	90	0.937
GGT (IU/L)	39	13	91.0 (46.0 – 136.0)	66.0 (48.0 – 100.0)	0.512	72	69	1.000
LDH (IU/L)	28	6	522.5 (399.8 – 687.0)	500.5 (402.2 – 672.2)	0.878	96	100	1.000

Magnesium (mmol/L)	39	13	0.9 (0.9 – 1.0)	1.0 (0.8 – 1.1)	0.657	33	46	0.618
Sodium (mmol/L)	39	13	136.0 (134.0 – 139.0)	137.0 (136.0 – 138.0)	0.367	38	23	0.501
NT-proBNP (ng/L)	23	5	400.0 (164.5 – 1867.0)	427.0 (126.0 – 3916.0)	0.676	74	80	1.000
Procalcitonin (µg/L)	22	8	1.6 (0.5 – 11.8)	0.7 (0.3 – 2.5)	0.241	100	100	N/A
Phosphate (mmol/L)	39	13	1.1 (0.8 – 1.5)	1.2 (1.0 – 1.7)	0.336	46	54	0.873
Potassium (mmol/L)	39	13	4.4 (4.0 – 4.9)	4.7 (3.8 – 5.4)	0.695	28	38	0.729
Troponin T (ng/L)	35	12	24.0 (14.5 – 54.0)	32.0 (16.0 – 90.2)	0.472	74	92	0.389
Total protein (g/L)	39	13	72.0 (67.0 – 73.0)	66.0 (60.0 – 71.0	0.044	8	15	0.786
Urea (mmol/L)	39	13	8.6 (5.0 – 15.2)	17.6 (9.9 – 19.1)	0.076	59	85	0.178